- ISIN
- US04623U1025
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
Highlights
- Market Cap
- $24.21B
- Enterprise Value
- $25.51B
- EPS (TTM)
- ¥172.03
- PE Ratio
- 12.65
- PEG Ratio
- 0.08
- Total Revenue (TTM)
- ¥2.27T
- Gross Profit (TTM)
- ¥1.69T
- EBITDA (TTM)
- ¥445.01B
- Year Range
- $9.22 - $17.35
- ROA (TTM)
- 8.63%
- ROE (TTM)
- 16.81%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
ALPMY Performance Chart
Astellas Pharma Inc (ALPMY) is up 1.4% since the beginning of the year. At $13 per share, ALPMY is trading 22.4% below its 52-week high of $17. Investors who bought $1,000 worth of ALPMY shares 5 years ago would now be looking at an investment worth $792.
Loading charts...
Returns By Period
Astellas Pharma Inc (ALPMY) has returned 1.35% so far this year and 45.94% over the past 12 months. Over the last ten years, ALPMY has returned -0.31% per year, falling short of the S&P 500 Index benchmark, which averaged 13.88% annually.
Astellas Pharma Inc
- 1D
- 0.15%
- 1M
- -5.21%
- YTD
- 1.35%
- 6M
- 1.89%
- 1Y
- 45.94%
- 3Y*
- -2.47%
- 5Y*
- -4.56%
- 10Y*
- -0.31%
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
ALPMY Monthly Returns History
Based on dividend-adjusted daily data since Dec 18, 2008, ALPMY's average daily return is +0.01%, while the average monthly return is +0.11%. At this rate, an investment would double in approximately 52.5 years.
Historically, 52% of months were positive and 48% were negative. The best month was Oct 2019 with a return of +21.1%, while the worst month was May 2013 at -77.8%. The longest winning streak lasted 6 consecutive months, and the longest losing streak was 8 months.
On a daily basis, ALPMY closed higher 49% of trading days. The best single day was Aug 7, 2023 with a return of +10.6%, while the worst single day was May 13, 2013 at -75.7%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 4.29% | 19.12% | -1.76% | -11.84% | -0.84% | -5.01% | 1.35% | ||||||
| 2025 | 0.21% | 0.31% | 2.13% | 2.59% | -0.81% | -0.81% | 6.05% | 5.90% | -0.64% | -4.04% | 20.21% | 5.90% | 41.23% |
| 2024 | -2.52% | -5.78% | -1.65% | -11.16% | 2.72% | 0.51% | 17.75% | 6.89% | -5.77% | 2.01% | -11.13% | -6.94% | -17.10% |
| 2023 | -3.17% | -4.63% | 1.39% | 5.81% | 4.99% | -5.71% | -1.61% | 3.49% | -8.52% | -8.38% | -4.18% | -2.14% | -21.50% |
| 2022 | -0.74% | 3.28% | -6.59% | -2.63% | 4.88% | -2.20% | 0.06% | -9.38% | -5.53% | 3.98% | 11.54% | -1.94% | -6.82% |
| 2021 | 5.51% | -2.58% | -2.71% | -2.88% | 8.17% | 7.12% | -8.37% | 5.40% | -1.55% | 2.18% | -7.85% | 4.60% | 5.38% |
Benchmark Metrics
Astellas Pharma Inc has an annualized alpha of -3.91%, beta of 0.40, and R2 of 0.05 versus S&P 500 Index. Calculated based on daily prices since December 18, 2008.
- This stock participated in 55.76% of S&P 500 Index downside but only 6.13% of its upside - more exposed to losses than it benefited from rallies.
- Beta of 0.40 may look defensive, but with R2 of 0.05 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
- R2 of 0.05 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -3.91%
- Beta
- 0.40
- R²
- 0.05
- Upside Capture
- 6.13%
- Downside Capture
- 55.76%
Return for Risk
Risk / Return Rank
ALPMY ranks 80 for risk / return — better than 80% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Astellas Pharma Inc (ALPMY) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| ALPMY | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -0.42 | ||
| Sortino ratioReturn per unit of downside risk | -0.47 | ||
| Omega ratioGain probability vs. loss probability | 1.28 | 1.37 | -0.09 |
| Calmar ratioReturn relative to maximum drawdown | 2.17 | 2.78 | -0.61 |
| Martin ratioReturn relative to average drawdown | 5.85 | 12.44 | -6.59 |
Dividends
Dividend History
Astellas Pharma Inc provided a 0.00% dividend yield over the last twelve months, with an annual payout of $0.00 per share.
| Period | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend | $0.00 | $0.26 | $0.25 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.15 | $0.30 |
Dividend yield | 0.00% | 1.93% | 2.56% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 1.20% | 2.18% |
Monthly Dividends
The table displays the monthly dividend distributions for Astellas Pharma Inc. The dividends shown in the table have been adjusted to account for any splits that may have occurred.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | ||||||
| 2025 | $0.00 | $0.00 | $0.26 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.26 |
| 2024 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.25 | $0.00 | $0.00 | $0.00 | $0.25 |
| 2023 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2022 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| 2021 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Astellas Pharma Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Astellas Pharma Inc was 83.67%, occurring on Apr 15, 2024. The portfolio has not yet recovered.
The current Astellas Pharma Inc drawdown is 75.12%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2024 bear market2024 | -83.67%Apr 2024 | 10y 11mo | — | 13y 1moMay 2013 - now |
Financial crisis2007–2009 | -25.38%Mar 2009 | 1mo 14d | 4mo 27d | 6mo 11dJan 2009 - Aug 2009 |
2010 bear market2010 | -23.74%Jun 2010 | 7mo 22d | 1y 7mo | 2y 3moOct 2009 - Feb 2012 |
2012 correction2012 | -14.26%Dec 2012 | 3mo 18d | 1mo 14d | 5mo 2dSep 2012 - Feb 2013 |
2013 correction2013 | -11.52%May 2013 | 1d | 6d | 7dMay 2013 - May 2013 |
Drawdown Indicators
| ALPMY | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -83.67% | -56.78% | -26.89% |
Max Drawdown (1Y)Largest decline over 1 year | -21.28% | -9.10% | -12.18% |
Max Drawdown (3Y)Largest decline over 3 years | -40.38% | -18.90% | -21.48% |
Max Drawdown (5Y)Largest decline over 5 years | -49.11% | -25.43% | -23.68% |
Max Drawdown (10Y)Largest decline over 10 years | -49.67% | -33.92% | -15.75% |
Current DrawdownCurrent decline from peak | -75.12% | -1.80% | -73.32% |
Average DrawdownAverage peak-to-trough decline | -58.44% | -10.71% | -47.73% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 7.88% | 2.03% | +5.85% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Astellas Pharma Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Astellas Pharma Inc is priced in the market compared to other companies in the Drug Manufacturers - General industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PE Ratio
The chart displays the Price-to-Earnings (P/E) ratio for ALPMY, comparing it with other companies in the Drug Manufacturers - General industry. Currently, ALPMY has a P/E ratio of 12.7. This P/E ratio is considered low compared to industry peers, which may suggest that the stock is undervalued or that the company has weaker growth prospects.
PEG Ratio
The chart shows the Price/Earnings to Growth (PEG) ratio for ALPMY compared to other companies in the Drug Manufacturers - General industry. ALPMY currently has a PEG ratio of 0.1. This PEG ratio is low compared to industry peers, which could indicate the stock is undervalued relative to its expected growth.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for ALPMY relative to other companies in the Drug Manufacturers - General industry. Currently, ALPMY has a P/S ratio of 1.7. This P/S ratio is low compared to the industry average. It may indicate that the stock is undervalued relative to its revenue, or that the market expects slower growth or lower margins.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for ALPMY in comparison with other companies in the Drug Manufacturers - General industry. Currently, ALPMY has a P/B value of 2.1. This P/B ratio is in line with the industry average, suggesting the stock is valued fairly in relation to its book value.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with ALPMY
Add Astellas Pharma Inc to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with ALPMY